Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting

The 20th annual IMS meeting dedicated a session to the practical aspects regarding T-cell redirected therapies, specifically chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies/T-cell engagers (bsAbs/TCEs), an increasing number of which have been introduced recently into the relapsed/refractory MM (RRMM) treatment landscape. This article summarizes the discussions and key take-home messages from this session. Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies.